Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
ConditionCoronary Artery Bypass Graft
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBrigham and Women's Hospital
About this trial
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Eligibility criteria
Qualifiers
Age ≥18 years
Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
Age ≥65 years
eGFR <45 ml/min/1.73m2
Disqualifiers
ALT >3-fold the upper limit of normal
eGFR <30 ml/min/1.73m2 or ESKD on dialysis
Hemoglobin <8 g/dl
History of gastric bypass or malabsorption
Trial design
Treatments tested in this trial
- MIB-626
- Placebo
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Brigham and Women's Hospital
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov